- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04787120
Squid Liquid Embolic Agent for the Embolization of Abdominopelvic Arterial Bleeding Syndrome (SQUIDperi Study) (SQUIDperi)
A France-based Study for Squid Liquid Embolic Agent for the Embolization of Abdominopelvic Arterial Bleeding Syndrome: SQUIDperi Study: A Non-interventional, Prospective, Single-arm, Multicenter Study
Abdominopelvic bleeding can occur due to numerous causes including for the vast majority, trauma, surgery complications and tumors. Interventional radiologists often exclude arterial acute hemorrhage using cyanoacrylate or a liquid embolic agent, but few prospective results have been published to assess their efficacy and safety. The historic and most studied liquid embolic agent to date is Onyx. Results in the treatment of acute peripheral non-neurologic hemorrhage have been detailed in a meta-analysis published in 2015. This systematic review found 19 articles presenting 131 patient cases and 150 lesions treated with Onyx from 2005 to August 2014. There were 11 case series and 8 case reports but no prospective trial. The most common presenting symptoms were of gastrointestinal (GI) origin (n = 51). Rebleeding of the baseline lesion occurred in 7/131 patients. No deaths resulting from complications of the embolic procedure were reported. One patient died of persistent hemoptysis after treatment with Onyx. No deaths were directly attributable to the use of Onyx.
During a peripheral embolization procedure with available embolic agents other than SQUIDPERI, residual feedings or collateral vessels became gradually less visible to the operator due to the high radiopacity of the liquid. It was therefore essential to develop an embolization system with lower radiopacity, or with radiopacity that decreases over time. Additionally, depending on the angioarchitecture and flow characteristics, it is important to have an embolic agent with various viscosities. SQUIDPERI is a liquid embolic agent with various viscosities and radiopacities. It is indicated for the embolization of lesions in the peripheral vasculature but its use is poorly reported as of today.
The purpose of this prospective non interventional multicenter study is to evaluate the safety and efficacy of SQUIDPERI for the treatment of abdominopelvic arterial acute bleeding or imminent risk of bleeding.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Romaric LOFFROY
- Phone Number: 03 80 29 33 58
- Email: romaric.loffroy@chu-dijon.fr
Study Locations
-
-
-
Dijon, France, 21000
- CHU Dijon Bourgogne
-
Contact:
- Romaric LOFFROY
- Phone Number: 03 80 29 33 58
- Email: romaric.loffroy@chu-dijon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient presenting with an arterial abdominopelvic bleeding or imminent risk of bleeding, including visceral, muscular or GI territories, requiring embolization, along with angiographic abnormalities
- Patient for whom the use of SQUIDperi had been decided for an embolization
- Patient or authorized representative dully informed and having no objection to the clinical data collection and medical file access
- Patient > 18 years
Exclusion Criteria:
- Patient with severe live failure
- Patient participating in another interventional study
- Vulnerable patients including pregnant women
- Patient not eligible for treatment with liquid embolic agent
- Patients presenting contra-indications to SQUIDperi as describes in the Informations For Use (IFU)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Individuals with arterial abdominopelvic bleeding
Arterial abdominopelvic bleeding or imminent risk of bleeding
|
Liquid embolic delivery syringes and micro-catheter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of embolization success at one month
Time Frame: 1 month
|
Defined as the absence of re-intervention for re-bleeding from the target artery/arteries embolized during the index procedure
|
1 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOFFROY BALT 2020-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Bleeding
-
BG Trauma Center TuebingenCompletedPolytrauma | Pelvic Ring Fracture | Pelvic BleedingGermany
-
Acibadem UniversityPamukkale University; Cukurova University; Gazi University; Baskent University; Ege... and other collaboratorsCompleted
-
Rajavithi HospitalCompletedInfertility, Female | Chronic Pelvic Pain | Abnormal Uterine BleedingThailand
-
Vanderbilt University Medical CenterWithdrawnDysmenorrhea | Adenomyosis | Heavy Uterine BleedingUnited States
-
Gaziosmanpasa Research and Education HospitalCompletedPelvic Pain | Isthmocele | Post-menstrual Spotting BleedingTurkey
-
BayerCompletedMenorrhagia, DysmenorrheaJapan
-
Saskatchewan Health Authority - Regina AreaUniversity of SaskatchewanRecruitingDysmenorrhea | Abnormal Uterine BleedingCanada
-
Washington University School of MedicineCompletedMetastasis | Gastrointestinal Bleeding | Malignancy | Pelvic Bleeding | Hemoptysis | Superior Vena Cava Syndrome | Mediastinal DiseaseUnited States
-
The University of Texas Health Science Center,...Not yet recruitingMenstrual Irregularity | Cesarean Section Complications | Pelvic Pain | Uterine Bleeding
-
University of South FloridaCompletedEndometrial Hyperplasia | Pelvic Organ Prolapse | Pelvic Pain | Adenomyosis | Pelvic Mass | Gynecologic Cancers | Uterine Leiomyomata | Other Abnormal Uterine and Vaginal BleedingUnited States